金城医药(300233.SZ)：米拉贝隆收到化学原料药上市申请批准通知书

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received approval for the marketing application of Mirabegron, a selective β-3 adrenergic receptor agonist, which is primarily used to treat overactive bladder (OAB) symptoms such as urinary incontinence, urgency, and frequency [1] Company Summary - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has recently received a notification from the National Medical Products Administration regarding the approval of the marketing application for the chemical raw material drug Mirabegron [1] - Mirabegron is indicated for the treatment of overactive bladder (OAB), addressing conditions like urinary incontinence, urgency, and frequency [1]